InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis
businessNews

InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis

Mar 30, 2021

STOCKHOLM, March 30, 2021 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the phase III study CONCLUDE. The study will evaluate the efficacy…


Continue Reading

Related Articles

businessNews WallSt

Foxconn’s Profit Misses Estimates as Pivot to Cars Accelerates

J Mar, 2021
businessNews WallSt

Double mutation of the Covid variant in India risks spreading to other countries, doctor says

J Mar, 2021
businessNews WallSt

Silicon Valley leaders think A.I. will one day fund free cash handouts. But experts aren’t convinced

J Mar, 2021

News You Missed

zerohedge

Nuclear Weapons Blazing: Britain Enters The US-China Fray

Mar 30, 2021 HEDGE
businessNews WallSt

Foxconn’s Profit Misses Estimates as Pivot to Cars Accelerates

Mar 30, 2021 HEDGE
WallSt

Hong Kong: What is China's 'patriot' plan for electoral reform?

Mar 30, 2021 HEDGE
WallSt

African talent recruitment company TalentQL joins Techstars to further global ambition

Mar 30, 2021 HEDGE
HEDGE accordingly